IP Library › Granted Patent US 9,610,347
Granted Patent B2
US 9,610,347 · App. 14/640,457 · Granted Apr 4, 2017

Vaccination response for immunodeficiency or high cortisol

Inventors: John Edgar Menear (Santa Cruz, CA); Joseph Ramaekers (Aptos, CA)
Assignee: CortControl
A61K39/39A61K39/0225A61K39/12A61K35/744A61K2039/55516A61K2039/55594C12N2750/14334C12N2760/20134
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,610,347
App. No.
14/640,457
Granted
Apr 4, 2017
Kind
B2
Abstract

A method of improving a human's response to vaccination with a vaccine enhancing food. This food contains at least transfer factor and lactic acid generating bacteria, and in some embodiments includes glucans. The vaccine enhancing food may be consumed before, during, or after the vaccination. The results are an improvement in the vaccine titer, a slower decay of titer, longer periods of immunity, and fewer needed boosters.

Claims (17)

1. A method of increasing the antibody production of a vaccine for a human with a formulation, comprising:

preparing the formulation, wherein

said formulation comprises at least transfer factor and lactic acid generating bacteria, wherein

said transfer factor in each dosage is present at 0.05 to 50 mg per pound of said human's body weight, and

said lactic acid generating bacteria in each said dosage is present at 0.47-10 mg per pound of said human's body weight;

incorporating said formulation into a solution for injection, into a food for consumption, or into a liquid for consumption; and

administering the formulation to said human before, during, or after the vaccine is administered, wherein more antibodies are created by the vaccine plus formulation than are created by the vaccine without the formulation.

2. The method of claim 1 further comprising measuring a vaccine antibody titer to quantify said increasing.

3. The method of claim 2 wherein said antibody titer is specific to any one disease selected from the group consisting of bordetella pertussis, haemophilus influenzae b, neisseria meningitides , poliovirus, streptococcus pneumoniae , tetanus toxoid, diphtheria toxoid, rabies virus, polio, measles, mumps, rubella, and human papillomavirus.

4. The method of claim 2 wherein said measuring of said vaccine antibody titer is performed 10-60 days after administration of said vaccine.

5. The method of claim 1 wherein said formulation further comprises one or more additives selected from the group consisting of glucans, hetero-polysaccharides, vitamins, electrolytes, probiotics, and immune modulators.

6. The method of claim 5 wherein said glucans are derived from mushrooms or hybrid mushrooms.

7. The method of claim 5 wherein said glucans are present at 0.05 to 50 mg per pound of said human's body weight.

8. The method of claim 1 wherein said administering occurs 3-30 days before said vaccine is administered.

9. The method of claim 1 wherein said administering continues between five times per day and once per week for 1 to 60 days after said vaccine is administered.

10. The method of claim 9 wherein said administering continues after said 60 days.

11. The method of claim 1 further administering a booster vaccine that is given within 120 days of the first vaccine.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2015
From: MENEAR, JOHN E
To: CORTCONTROL
Reel/Frame 035104/0014 →
Continuity (13)
Continuation In Part 13877309 · Jun 3, 2013
Continuation In Part 12631745 · Dec 4, 2009
Continuation 11492464 · Jul 24, 2006
Continuation In Part 11106054 · Apr 13, 2005
Continuation 11237316 · Sep 27, 2005
Division 10136854 · Apr 30, 2002
Continuation In Part 09847036 · Apr 30, 2001
Provisional Application 61389190 · Oct 1, 2010
Provisional Application 61389230 · Oct 2, 2010
Provisional Application 60701860 · Jul 22, 2005
Provisional Application 60573113 · May 20, 2004
Provisional Application 60649363 · Feb 1, 2005
Related Publication 20150174241A1 · Jun 25, 2015